Evidence map›Paper›PMID 38662335›Full record

ArticleDrug delivery and translational research2025

Human mesenchymal stromal cells-laden crosslinked hyaluronic acid-alginate bioink for 3D bioprinting applications in tissue engineering.

Cristina Galocha-León, Cristina Antich, Ana Voltes-Martínez, Juan A Marchal, Mireia Mallandrich, Lyda Halbaut, Eliana B Souto, Patricia Gálvez-Martín, Beatriz Clares-Naveros

Open access · hybridAbstract read
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Cristina Galocha-León *Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, University Campus of Cartuja, 18071, Granada, Spain.
Cristina Antich *Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, 18100, Granada, Spain.
Ana Voltes-Martínez *Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, 18100, Granada, Spain.
Juan A MarchalBiopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, 18100, Granada, Spain.
Mireia MallandrichDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.
Lyda HalbautDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.
Eliana B SoutoLaboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, 4050-313, Porto, Portugal. ebsouto@ff.up.pt.ORCID 0000-0002-9737-6017
Patricia Gálvez-Martín *Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, University Campus of Cartuja, 18071, Granada, Spain.
Beatriz Clares-Naveros *Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, University Campus of Cartuja, 18071, Granada, Spain. beatrizclares@ugr.es.
Universidad de Granada · ESInstitut de Nanociència i Nanotecnologia de la Universitat de BarcelonaUniversidade do Porto · PT

Funding

FCT-Fundação para a Ciência e a Tecnologia, I.P., Lisbon, Portugal FCT-Fundação para a Ciência e a Tecnologia, I.P., Lisbon, PortugalMinistry of Economy and Competitiveness (FEDER funds), grant number RTC-2016-5451-1; Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds), grant numbers DTS19/00143 and DTS17/00087); Consejería de Economía, Conocimiento, Emp Ministry of Economy and Competitiveness (FEDER funds), grant number RTC-2016-5451-1; Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds), grant numbers DTS19/00143 and DTS17/00087); Consejería de Economía, Conocimiento, Emp
6 · The paper itself

Abstract

Three-dimensional (3D) bioprinting is considered one of the most advanced tools to build up materials for tissue engineering. The aim of this work was the design, development and characterization of a bioink composed of human mesenchymal stromal cells (hMSC) for extrusion through nozzles to create these 3D structures that might potentially be apply to replace the function of damaged natural tissue. In this study, we focused on the advantages and the wide potential of biocompatible biomaterials, such as hyaluronic acid and alginate for the inclusion of hMSC. The bioink was characterized for its physical (pH, osmolality, degradation, swelling, porosity, surface electrical properties, conductivity, and surface structure), mechanical (rheology and printability) and biological (viability and proliferation) properties. The developed bioink showed high porosity and high swelling capacity, while the degradation rate was dependent on the temperature. The bioink also showed negative electrical surface and appropriate rheological properties required for bioprinting. Moreover, stress-stability studies did not show any sign of physical instability. The developed bioink provided an excellent environment for the promotion of the viability and growth of hMSC cells. Our work reports the first-time study of the effect of storage temperature on the cell viability of bioinks, besides showing that our bioink promoted a high cell viability after being extruded by the bioprinter. These results support the suggestion that the developed hMSC-composed bioink fulfills all the requirements for tissue engineering and can be proposed as a biological tool with potential applications in regenerative medicine and tissue engineering.

Indexed as

AlginatesBioprintingCell SurvivalHyaluronic AcidMesenchymal Stem CellsPrinting, Three-DimensionalTissue EngineeringBiocompatible MaterialsCell ProliferationCells, CulturedGlucuronic AcidHumansInkPorosityTissue ScaffoldsAlginatesBiocompatible MaterialsGlucuronic AcidHyaluronic AcidBioinkBiomaterialsHuman mesenchymal stromal cellsRegenerative medicineTissue engineering

Identifiers

PMID38662335
PMCPMC11614963
OpenAlexW4395465970

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.